Tyra Biosciences (NASDAQ:TYRA) Shares Up 6.2%

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares were up 6.2% during mid-day trading on Monday . The company traded as high as $16.98 and last traded at $16.98. Approximately 42,326 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 145,459 shares. The stock had previously closed at $15.99.

Analyst Ratings Changes

TYRA has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, June 5th. Wedbush reissued an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, May 10th. Finally, Oppenheimer restated an “outperform” rating and issued a $28.00 price objective (up from $25.00) on shares of Tyra Biosciences in a report on Monday, May 13th.

Tyra Biosciences Price Performance

The business has a 50 day moving average price of $17.57 and a two-hundred day moving average price of $16.53. The stock has a market cap of $907.89 million, a PE ratio of -10.27 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. On average, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Daniel Bensen sold 3,502 shares of Tyra Biosciences stock in a transaction on Monday, June 10th. The shares were sold at an average price of $20.00, for a total value of $70,040.00. Following the sale, the chief operating officer now owns 427,981 shares in the company, valued at $8,559,620. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. lifted its stake in shares of Tyra Biosciences by 1,244.2% in the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after buying an additional 1,916 shares in the last quarter. AJOVista LLC bought a new position in Tyra Biosciences in the 4th quarter valued at approximately $59,000. Exchange Traded Concepts LLC boosted its stake in Tyra Biosciences by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after purchasing an additional 2,417 shares during the last quarter. Corton Capital Inc. bought a new stake in shares of Tyra Biosciences in the 3rd quarter worth $152,000. Finally, Fishman Jay A Ltd. MI purchased a new position in shares of Tyra Biosciences in the first quarter worth $246,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.